A polygenic risk score for breast cancer in U.S. Latinas and Latin-American women
Yiwey Shieh(University of California, San Francisco), Susan L. Neuhausen(City of Hope), Katie M. Marker(Berkeley College), Magdalena Echeverry(University of Tolima), Luis G. Carvajal‐Carmona(Cancer Research UK), Ana P. Estrada-Florez(University of Tolima), Jeffrey N. Weitzel(Cancer Genetics (United States)), Lawrence H. Kushi(Kaiser Permanente), Esther M. John, Mábel Bohórquez(Vita-Salute San Raffaele University), Elad Ziv(University of California, San Francisco), Christopher A. Haiman(University of Southern California), Sandro Casavilca‐Zambrano(Institute for Anthropological Research), Laura Fejerman(University of California, San Francisco), Scott Huntsman(University of California, San Francisco), Javier Torres(Mexican Social Security Institute), Sarah Sawyer(Natera (United States)), Paul C. Lott(University of Utah), Guadalupe Polanco‐Echeverry(University of California, Davis), Gabriela Torres-Mejı́a(Instituto Nacional de Salud Pública), Juan Carlos Martı́nez-Chéquer(Mexican Social Security Institute), Donglei Hu(University of California, San Francisco)
Cited by 21
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention: Reducing the Risk of Cancer With Healthy Food Choices and Physical Activity
|CA A Cancer Journal for Clinicians|2006|1.9k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k